Clinical trials
Advanced Pancreatic Cancer clinical trials
Below are recruiting advanced pancreatic cancer clinical trials, each written for real people, not researchers. We’re tracking 406 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05132504RecruitingPhase 2
Pre-surgery chemotherapy and immunotherapy for operable pancreatic cancer
This Phase 2 trial tests giving chemotherapy plus pembrolizumab (an immunotherapy) before surgery, to shrink or control potentially removable pancreatic cancer. The goal is to improve outcomes while making sure the cancer can still be safely removed by surgery.
Houston, TexasAges 18 years+ - NCT06538857RecruitingPhase 2
Study of CEB-01 for resectable pancreatic cancer
This trial tests an experimental drug called CEB-01 in people with pancreatic cancer that can be surgically removed. It aims to see if adding this drug to surgery improves outcomes.
Barcelona, CataloniaAges 18 years+ - NCT07481383RecruitingPhase 1
Implant device for chemo delivery in advanced pancreatic cancer
This trial tests an implantable device that delivers chemotherapy (gemcitabine) directly to pancreatic tumors. It may offer a new treatment option for people with non-metastatic, advanced pancreatic cancer that cannot be surgically removed.
Ann Arbor, MichiganAges 18 years+ - NCT07656571Recruiting
Green dye vs standard surgery for pancreas tail tumors
This trial compares standard laparoscopic surgery to surgery using a green dye that helps the surgeon see the pancreas more clearly. It may help patients needing removal of tumors in the body or tail of the pancreas.
AlexandriaAges 18 years+ - NCT06384560RecruitingPhase 1/Phase 2
Triple therapy before surgery for pancreatic cancer
This trial tests a combination of chemotherapy, radiation, and immunotherapy (pembrolizumab) before surgery for pancreatic cancer that can be removed. It aims to see if this triple therapy helps shrink tumors and improve survival.
AmsterdamAges 18 years+ - NCT06005493RecruitingPhase 1/Phase 2
Study of AZD5863 for advanced stomach, esophagus, or pancreatic cancer
This trial is testing an investigational drug called AZD5863 for people whose stomach, esophagus, or pancreatic cancer has spread and hasn't responded to at least one previous treatment. The study aims to see if targeting a protein called Claudin 18.2 on tumor cells can help shrink or slow the cancer.
Jacksonville, FloridaAges 18 years+ - NCT06245330RecruitingPhase 1/Phase 2
Study of AST-001 for advanced solid tumors
This trial is testing a new drug called AST-001 for people with advanced solid tumors (including pancreatic cancer) that have not responded to standard treatments. The study aims to find the right dose and see how well the drug works.
Changchun, JinlinAges 18–70 - NCT06428409RecruitingPhase 1/Phase 2
A study of MK-2870 for several gastrointestinal cancers
This trial is testing a new drug called MK-2870, alone or with other treatments, for people with advanced colorectal, pancreatic, or bile duct cancer. It aims to see if the drug can help shrink or control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT07249775Recruiting
Study of new drug FID-022 for pancreatic cancer
This trial tests a new study drug called FID-022 for people with pancreatic cancer. It is a first-in-human study, meaning it is the first time this drug is being tested in people, and researchers want to see if it is safe and how it works.
Tampa, FloridaAges 18 years+ - NCT07106827RecruitingPhase 1
Study of a new drug for advanced or resistant solid tumors
This trial tests a new drug, GV20-0251, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and helpful.
Chengdu, SichuanAges 18 years+ - NCT06050317RecruitingPhase 2
Sintilimab plus chemo and radiation for inoperable pancreatic cancer
This trial combines the immunotherapy drug sintilimab with chemotherapy and radiation for people with inoperable locally advanced pancreatic cancer who have not received prior systemic treatment. The goal is to see if this combination shrinks tumors and improves outcomes.
Jinan, ShandongAges 18–75 - NCT05288205RecruitingPhase 1/Phase 2
JAB-21822 plus JAB-3312 for KRAS G12C solid tumors
This Phase 1/2a trial tests two investigational pills (JAB-21822 and JAB-3312) in people with advanced solid cancers that have a KRAS G12C mutation. It’s for cases where standard treatments have failed or aren’t suitable, to see if the drugs can shrink tumors and improve outcomes.
Hefei, AnhuiAges 18 years+ - NCT07226856RecruitingPhase 2
New combo for advanced pancreatic cancer
This trial tests a new drug (BMS-986340) plus standard chemo for people whose pancreatic cancer has spread or come back. The goal is to see if this combination works better.
Scottsdale, ArizonaAges 18 years+ - NCT06900595RecruitingPhase 2
Cabozantinib with immunotherapy for advanced adrenal cancer
This trial tests adding the targeted drug cabozantinib to the immunotherapy cemiplimab for people with advanced adrenocortical carcinoma that cannot be removed by surgery or has spread. It checks if the combination works better than cabozantinib alone.
La Jolla, CaliforniaAges 12 years+ - NCT06562192RecruitingPhase 1
Testing a radioactive drug for advanced pancreatic, lung, breast, and colorectal cancers
This trial tests a new radioactive drug (177Lu-NNS309) for people with advanced pancreatic, lung, breast, or colorectal cancer that has not responded to prior treatments. It aims to see if the drug can target and shrink tumors.
Birmingham, AlabamaAges 18–100 - NCT05208762RecruitingPhase 1
PD-L1 antibody drug study for advanced lung and head/neck cancers
This Phase 1 trial tests a new experimental drug (PF-08046054/SGN-PDL1V) in people with advanced solid tumors that have not responded to standard treatment or can’t use it. It is designed to see how the drug works and how safe it is, with a focus on tumors that have PD-L1 seen on prior lab testing.
Birmingham, AlabamaAges 18 years+ - NCT06892054RecruitingPhase 1
Targeted therapy plus chemo for advanced pancreatic cancer
This study tests a new targeted drug called sotorasib combined with standard chemotherapy for people with advanced pancreatic cancer that has a specific KRAS G12C mutation. The goal is to see if the combination works better than chemotherapy alone.
Avignon, FranceAges 18 years+ - NCT03080974RecruitingPhase 2
Study tests immunotherapy plus electroporation for advanced pancreatic cancer
This Phase 2 study looks at whether adding immunotherapy to a procedure called irreversible electroporation can help treat stage III pancreatic cancer. You might be eligible if you have measurable tumors and can safely undergo the procedure.
Louisville, KentuckyAges 18 years+ - NCT05052671Recruiting
Blood test for residual cancer in resectable pancreatic cancer
This trial studies a blood test that looks for tiny traces of cancer-related DNA (called ctDNA) in people with pancreatic cancer that can be removed with surgery. The goal is to see whether this test can better predict how the cancer behaves and guide treatment decisions around surgery.
Oklahoma City, OklahomaAges 18–99 - NCT05841420RecruitingPhase 2
Lower-intensity chemo for fragile pancreatic cancer patients
This Phase 2 trial compares a standard gemcitabine approach versus a reduced-dose combination chemotherapy for people with pancreatic cancer that can’t be removed by surgery. It aims to find a treatment that works while being safer for “fragile” patients who can’t tolerate full-dose chemotherapy.
AalborgAges 18 years+ - NCT06128551RecruitingPhase 1/Phase 2
Testing two targeted drugs for KRAS G12C advanced cancer
This study tests two oral medicines (elironrasib and daraxonrasib) given alone or together to see if they can shrink tumors or slow down cancer growth in people with advanced solid tumors that have a KRAS G12C mutation. It is for people who have already tried other treatments.
Duarte, CaliforniaAges 18 years+ - NCT06778863RecruitingPhase 1
A study of CLSP-1025 for adults with certain solid tumors
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
Scottsdale, ArizonaAges 18 years+ - NCT05191940Recruiting
Radiation for advanced pancreatic cancer you can’t remove by surgery
This trial studies how well radiation therapy works for pancreatic cancer that is locally advanced (near important blood vessels) and cannot be removed with surgery. It may help shrink or control the cancer when surgery isn’t an option.
Wiener Neustadt, Lower AustriaAges 18 years+ - NCT04622423Recruiting
Advanced therapies for colon or pancreas liver metastases
This study tests advanced treatments for cancer that has spread to the liver, either from colon cancer or pancreatic cancer. It may help by targeting liver tumors using treatment plans and, for some participants, liver tissue samples.
Milan, MilanAges 18 years+
Hear when a new Advanced Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced pancreatic cancer?
- Yes. Clin2 currently lists 406 recruiting advanced pancreatic cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced pancreatic cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced pancreatic cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.